VLRS sees June traffic dip 1.4% despite a 0.6% capacity rise, pushing its load factor down to 83.9% from 85.6% last year.

Wix teams up with Monotype to expand its font library, fueling creative freedom, as it bets on AI, Studio and global commerce growth.

VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keytruda.

GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.

BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.

Environmental, social, and governance (ESG) hasn't lost traction after exploding in popularity after the 2020 pandemic. Corporations are playing a bigger role in the issuance of ESG or “green” bonds, paving the way for opportunities in funds like the Vanguard ESG U.S. Corporate Bond ETF (VCEB).

Much credit goes to large-caps for pulling the broad market out of April's sell-off abyss. But traders looking for other plays this summer may want to consider downsizing with small- and midcap plays.

CRDO jumps 144% in three months as AI momentum, strong product demand and upbeat outlook fuel investor confidence.

JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.

CCI's tower growth, strong tenant leases and solid balance sheet drive a 13% stock surge YTD.

FDX edges past UPS on valuation, cost-cutting gains, and financial strength as both firms battle weak parcel demand.

Alta Equipment (ALTG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Fastenal (FAST), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.

Get a deeper insight into the potential performance of FB Financial (FBK) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Nearly 35,000%. That's how much Nvidia's share price has risen over the last decade, trouncing the S&P 500's roughly 260% advance, including reinvested dividends.

Hovnanian Enterprises remains a 'strong buy' due to its compelling valuation and management's effective leverage reduction, despite recent operational headwinds. The company faces near-term challenges: declining home prices, lower net income, and rising costs, but these are industry-wide and cyclical. Management's asset-light strategy—controlling more lots via options—positions Hovnanian for future growth while keeping debt manageable.

Late last month, Lesaka Technologies announced plans to acquire Bank Zero Mutual Bank. The South Africa-based fintech has just divested its last main non-core asset, paving the way for a further acceleration of its transformation. The Bank Zero deal stands to be even more transformative for LSAK, as the transaction could enable the company to materially reduce its borrowing costs.

CRM's Data Cloud tops $1B in ARR with 120% YoY growth, powering AI tools and driving major deals across its platform.

I sold my TSMC stock for a weighted 32.4% gain over the past three months. I've redeployed profits predominantly into healthcare, but also into higher-alpha tech. TSMC has a remarkable macro growth backdrop, but the stock is way too expensive right now to buy. I'm expecting a 10-15% return for TSMC stock over the next 12 months, that's why I encourage my readers to look elsewhere for higher-alpha opportunities.

Delek's heavy reliance on the Permian Basin can cause some challenges in the long run. Its increasing exposure to third-party clients coupled with its fee-based business model allows it to diversify and stabilize revenues. Its fundamentals stay decent, justifying its valuation and ensuring sustainability of cash distributions.